Imagine a coffee machine, but instead of espresso, it prints a single pill containing several different medicines tailored exactly to your body. It uses a special 3D printing method to create tiny compartments that release drugs at different times. This means patients don't have to swallow a handful of different tablets every day.
Patients with chronic diseases often struggle with 'polypharmacy', taking multiple pills which leads to dosing errors and poor adherence. Current personalized medicine is too expensive and hard to scale due to manufacturing and stability issues.
A lab-scale proof-of-concept desktop printing machine that uses powdered drugs and bioresorbable polymers to create customized polypills.
If you are a specialty drug producer dealing with the inefficiency of one-size-fits-all medication — this project developed a 3D printing platform that creates polypills with tailored release profiles. This allows for precise dosing of multiple active ingredients in one pill, reducing side effects.
If you are a hospital pharmacy operator dealing with poor patient adherence to complex medication regimens — this project developed a desktop-size printing machine that produces customized pills on-demand. This simplifies treatment for chronic conditions like diabetes or cardiovascular diseases.
If you are a hardware manufacturer dealing with the lack of digital interfaces in drug delivery — this project developed a system with a bi-directional digital information flow. This enables the creation of a lab-scale proof-of-concept prototype for clinical settings.
Based on available project data, specific pricing or cost figures for the device are not provided.
The project focuses on a desktop-size system for local preparation in clinical settings and pharmacies, rather than mass industrial production.
Based on available project data, there is no specific information regarding IP or licensing agreements.
The project aims to overcome regulatory hurdles by using a digital technology interface and precise dosing to ensure stability and efficacy.
It provides a bi-directional digital information flow to track patient dosing procedures and gather data for evidence-based medicine.
The consortium consists of 6 partners across 4 countries, showing a balanced mix of research and commercial interests with a 33% industry ratio (2 SMEs). Led by Fraunhofer, the group combines academic knowledge from 3 universities with applied research, suggesting a strong pipeline from lab development to technical validation.
Contact Fraunhofer Gesellschaft zur Förderung der Angewandten Forschung EV
Contact us to explore licensing opportunities for adaptive microprinting in pharma.
